Business Wire

OR-RADISYS

21.2.2024 14:01:28 CET | Business Wire | Press release

Share
Radisys Unveils 5G Advanced Wireless Connectivity Software for Industry 4.0 and Private 5G

Radisys® Corporation, a global leader of open telecom solutions, today announced the launch of its groundbreaking 5G Advanced Wireless Connectivity Software designed specifically for Industry 4.0 and private 5G networks. This significant advancement in the evolution of enterprise solutions offers unparalleled capabilities to establish private networks with enhanced performance, ease of deployability and management, and data protection with guaranteed Quality of Service (QoS). Radisys’ innovative 5G Advanced Wireless Connectivity software enables enterprises to meet the surging demand for private 5G and Industry 4.0 solutions capable of meeting evolving business needs.

By seamlessly integrating licensed, lightly licensed (CBRS) and unlicensed Wifi access via N3IWF, the advanced software solution delivers low latency, cloud-native solutions for both the RAN and Core networks. The cloudification of both RAN and Core networks offers flexible deployment options that allow for segregated and collocated distribution units (DU), central units (CU) and user plane functions (UPF) within a Kubernetes cloud environment, with the additional capability of deploying CU and UPF in the public cloud. This streamlined approach facilitates automation and simplifies the deployment of 5G networks, ultimately reducing capital expenditure (CapEx) and operational expenditure (OpEx) for private and Industry 4.0 5G operators.

Key features include:

  • Time Sensitive Network (TSN) and 5G Ultra-Reliable Low Latency Communication (5G-URLLC) features for deterministic, low latency communication, targeted at Industry 4.0 automation requirements.
  • 5G Reduced Capability (RedCap) for connectivity of the low-cost sensors enabling smart manufacturing processes and more.
  • N3IWF (Non-3GPP Inter-working Function) to allow convergence of existing Wifi access with the 5G Core Network in enterprise and manufacturing sectors. Additionally, N3IWF enables integration of non-3GPP traditional and legacy access technologies with the 5G. This enhances accessibility and flexibility, providing a high-performance network solution for Industry 4.0 private and enterprise networks with reduced CapEx.
  • CBRS band support with ease of integration into CBRS networks via a scalable CBRS Domain Proxy to enable acceleration of CBRS deployment for private and enterprise networks.
  • Enabling intelligent Private 5G and Industry 4.0 solutions through advanced RAN functions controlled via ORAN E2 interface and pre-integrated with xApps/rApps and RIC platforms from different vendors.

“Recognizing the specific needs of Industry 4.0 and private 5G networks, Radisys continues to deliver innovative advanced 5G RAN and Core features to accelerate the adoption of 5G in these markets,” said Munish Chhabra, Head of Mobility Software and Services Business, Radisys. “Radisys remains committed to driving innovation in wireless technologies, empowering businesses to harness the full potential of Industry 4.0 and the future of connectivity for private and enterprise networks through its award-winning Connect RAN 5G Software solution.”

Meet with Radisys at MWC Barcelona

Experience Radisys’ disaggregated Connect RAN solutions, including demonstrations of its 5G Advanced Wireless Connectivity RAN software, at MWC Barcelona, Stand 2D50. To schedule a meeting with Radisys’ RAN experts, contact open@radisys.com.

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints, to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221279407/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye